Silexion Therapeutics Corp (SLXN): Nasdaq/NYSE listing notice — Silexion receives Nasdaq bid price deficiency notice; reverse split set for July 29

Silexion Therapeutics Corp

On July 18, 2025, Nasdaq notified Silexion that its ordinary shares' closing bid price was below $1.00 for 30 consecutive days.
Bid price deficiency will be considered by Nasdaq hearings panel in continued listing decision.
Shareholder-approved 1-for-15 reverse split effective after market close July 28; trading begins split-adjusted July 29.
Company must also meet $2.5M minimum shareholders' equity by September 19, 2025 to maintain listing.
Current trading of shares (SLXN) and warrants (SLXNW) unaffected at this time.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Silexion Therapeutics Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

July 18, 2025, Silexion Therapeutics Corp (the “ Company ” or “ Silexion ”) received a letter from the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the 30 consecutive business days preceding the letter, the closing bid price of the Company’s ordinary shares, par value $0.0009 per share (“ ordinary share s”), was below the minimum $1.00 per share required for continued listing on The Nasdaq Stock Market LLC under Nasdaq Listing Rule 5550(a)(2) (the “ bid price deficiency ”). The Staff indicated in the letter that

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Silexion Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001178913-25-002431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.